Highlights of This Issue 6059

SPECIAL FEATURES

CCR Translations

6061  Harnessing Immune Responses in the Tumor Microenvironment: All Signals Needed
       Dung T. Le and Elizabeth M. Jaffee
       See related article, p. 6286

6064  Test-Firing Ammunition for Spliceosome Inhibition in Cancer
       Scott M. Dehm
       See related article, p. 6296

CCR Perspectives in Drug Approval

6067  Enzalutamide for Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer Who Have Previously Received Docetaxel: U.S. Food and Drug Administration Drug Approval Summary

Molecular Pathways

6074  Molecular Pathways: Adipose Inflammation as a Mediator of Obesity-Associated Cancer
       Louise R. Howe, Kotha Subbaramaiah, Clifford A. Hudis, and Andrew J. Dannenberg

6084  Molecular Pathways: Induction of Polyploidy as a Novel Differentiation Therapy for Leukemia
       Diane S. Krause and John D. Crispino

Review

6089  Lessons Learned from Radiation Oncology Clinical Trials
       Fei-Fei Liu, for the workshop participants, Paul Okunieff, Eric J. Bernhard, Helen B. Stone, Stephen Yoo, C. Norman Coleman, Bhadrasain Vikram, Martin Brown, John Buatti, and Chandan Guha

HUMAN CANCER BIOLOGY

6101  Semaphorin 4F as a Critical Regulator of Neuroepithelial Interactions and a Biomarker of Aggressive Prostate Cancer
       Yi Ding, Dandan He, Diego Fioretti, Anna Frolov, Sue Hilsenbeck, Michael Ittmann, Dov Kadmon, Brian Miles, David Rowley, and Gustavo Ayala

6112  Prostate Cancer Progression Correlates with Increased Humoral Immune Response to a Human Endogenous Retrovirus GAG Protein

6126  Hypoxic Activation of the PERK/eIF2alpha Arm of the Unfolded Protein Response Promotes Metastasis through Induction of LAMP3
       Hilda Mujcic, Anika Nagelkerke, Kasper M.A. Rousshop, Stephen Chung, Naz Chaudary, Paul N. Span, Blaise Clarke, Michael Milosevic, Jenna Sykes, Richard P. Hill, Marianne Koritzinsky, and Bradley G. Wouters

CANCER THERAPY: PRECLINICAL

6138  Adrenomedullin Blockade Suppresses Growth of Human Hormone-Independent Prostate Tumor Xenograft in Mice
Combined Immunostimulatory Monoclonal Antibodies Extend Survival in an Aggressive Transgenic Hepatocellular Carcinoma Mouse Model


Glucocorticoid Receptor Antagonism as a Novel Therapy for Triple-Negative Breast Cancer

Maxwell N. Skor, Erin L. Wonder, Masha Kocherginsky, Anju Goyal, Ben A. Hall, Yi Cai, and Suzanne D. Conzen

Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma


Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non–Small Cell Lung Cancer

Takeshi Shimamura, Zhao Chen, Margaret Soucheray, Julian Carretero, Eiki Kikuchi, Jeremy H. Tchaicha, Yandi Gao, Katherine A. Cheng, Travis J. Cohoon, Jun Qi, Esra Akbay, Alec C. Kimmelman, Andrew L. Kung, James E. Bradner, and Kwok-Kin Wong

Targeted Nanomedicine for Suppression of CD44 and Simultaneous Cell Death Induction in Ovarian Cancer: An Optimal Delivery of siRNA and Anticancer Drug

Vatsal Shah, Oleh Taratula, Olga B. Garbuzenko, Olena R. Taratula, Lorna Rodriguez-Rodriguez, and Tamara Minko

Combination Therapy with a Second-Generation Androgen Receptor Antagonist and a Metastasis Vaccine Improves Survival in a Spontaneous Prostate Cancer Model

Andressa Ardiani, Benedetto Farsaci, Connie J. Rogers, Andy Prottter, Zhimin Guo, Thomas H. King, David Apelian, and James W. Hodge

Overcoming IGF1R/IR Resistance through Inhibition of MEK Signaling in Colorectal Cancer Models

Sara A. Flanigan, Todd M. Pitts, Timothy P. Newton, Gillian N. Kulikowski, Aik Choon Tan, Martine C. McManus, Anna Spreatfito, Maria I. Kachaeva, Heather M. Selby, John J. Tenler, S. Gail Eckhardt, and Stephen Leong

JAK1/2 and Pan-Deacetylase Inhibitor Combination Therapy Yields Improved Efficacy in Preclinical Mouse Models of JAK2V617F-Driven Disease

Emeline Evrot, Nicolas Ebel, Vincent Romanet, Claudia Roelli, Rita Andreas, Zhiyan Qian, Arno Dölermeier, Ernesta Damussa, Dario Sterker, Robert Cozens, Francesco Hofmann, Masato Murakami, Fabienne Buffert, and Thomas Radimerski

Molecular Chaperone gp96 Is a Novel Therapeutic Target of Multiple Myeloma

Yunpeng Hua, Shai White-Gilbertson, Joshua Kellner, Saleh Rachidi, Saad Z. Usmani, Gabriela Chiossis, Ronald DePinho, Zihai Li, and Bei Liu

Associations between Single-Nucleotide Polymorphisms in the PI3K–PTEN–AKT–mTOR Pathway and Increased Risk of Brain Metastasis in Patients with Non–Small Cell Lung Cancer

Qianxia Li, Ju Yang, Qianqian Yu, Huihui Lu, Bo Liu, Huiluo Xiong, Guangyuan Hu, Jing Zhao, Xiagedin Yuan, and Zhongxing Liao

Validation of a Proliferation-Based Expression Signature as Prognostic Marker in Early Stage Lung Adenocarcinoma

Ignacio I. Wistuba, Carmen Behrens, Francesca Lombardi, Susanne Wagner, Junya Fujimoto, M. Gabriela Raso, Lorenzo Spaggiari, Domenico Galetta, Robyn Riley, Elisha Hughes, Julia Reid, Zaina Sangale, Steven G. Swisher, Neda Kalhor, Cesar A. Moran, Alexander Guitin, Jerry S. Lanchbury, Massimo Barberis, and Edward S. Kim
Promoter Hypomethylation of EpCAM-Regulated Bone Morphogenetic Protein Gene Family in Recurrent Endometrial Cancer
Ya-Ting Hsu, Fei Gu, Yi-Wen Huang, Joseph Liu, Jianhua Ruan, Rui-Lan Huang, Chiou-Min Wang, Chun-Liang Chen, Rohit R. JadHAV, Hung-Cheng Lai, David G. Mutch, Paul J. Goodfellow, Ian M. Thompson, Nameer B. Kirma, and Tim Hui-Ming Huang

Bendamustine and Rituximab in Relapsed and Refractory Hairy Cell Leukemia
Mauricio Burotto, Maryalice Stetler-Stevenson, Evgeny Arons, Hong Zhou, Wyndham Wilson, and Robert J. Kreitman

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung Cancer
Robert J. Cardnell, Ying Feng, Lixia Diao, You-Hong Fan, Fatemah Masrorpour, Jing Wang, Yuqiao Shen, Gordon B. Mills, John D. Minna, John V. Heymach, and Lauren A. Byers

LETTERS TO THE EDITOR

Conjunctival Melanomas Harbor BRAF and NRAS Mutations—Letter

Conjunctival Melanomas Harbor BRAF and NRAS Mutations—Response
Klaus G. Griewank, Henrike Westekemper, Bastian Schilling, Elisabeth Livingstone, Tobias Schimming, Antje Sucker, Uwe Hillen, Klaus-Peter Steuhl, Lisa Zimmer, and Dirk Schadendorf
ABOUT THE COVER

Cellular internalization of siRNA (red fluorescence) delivered by the nanocarrier (green fluorescence) specifically targeted to cancer cells. Superimposition of red (siRNA) and green (nanocarrier) fluorescence images gives yellow color. For details, see the article by Shah and colleagues on page 6193 of this issue.